NCT01168752View on ClinicalTrials.gov

Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

April 30, 2013

Study Completion Date

April 30, 2013

Conditions
CancerNeoplasmsSolid TumorsLymphoma
Interventions
DRUG

Debio 0932

"Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.~In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met."

Trial Locations (3)

21079

Centre Georges-François Leclerc, Dijon

31052

Institut Claudius Regaud, Toulouse

94805

Institut Gustave Roussy, Villejuif

Sponsors
All Listed Sponsors
lead

Debiopharm International SA

INDUSTRY